Table 2.
Trial enrollment for minorities vs. non-hispanic white for bladder and kidney cancer trials, 2015 to 2019.
| Race/ethnicity | No. of Trial participants | Enrollment fractiona | Odds ratio (95% CI) | P value |
|---|---|---|---|---|
| Bladder cancer | ||||
| Non-Hispanic White | 1,813 | 0.93% | Referent | |
| Black | 87 | 0.67% | 0.71 (0.57–0.88) | 0.002 |
| Hispanic | 69 | 0.65% | 0.69 (0.54–0.88) | 0.003 |
| Asian/Pacific Islander | 59 | 1.33% | 1.43 (1.10–1.86) | 0.006 |
| American Indian/Alaska Native | 4 | 0.45% | 0.48 (0.18–1.30) | 0.154 |
| Kidney cancer | ||||
| Non-Hispanic White | 1,076 | 0.76% | Referent | |
| Black | 75 | 0.32% | 0.42 (0.33–0.54) | <0.001 |
| Hispanic | 107 | 0.52% | 0.68 (0.55–0.83) | <0.001 |
| Asian/Pacific Islander | 32 | 0.68% | 0.89 (0.62–1.27) | 0.533 |
| American Indian/Alaska Native | 7 | 0.40% | 0.52 (0.24–1.10) | 0.090 |
a
Enrollment fraction – Defined as patients enrolled in trials/total cancer incidence for corresponding years.